BioSpace News Archive

Octave announced the presentation of data from 13 abstracts presented at the European Committee for Treatment and Research in Multiple Sclerosis Conference 2022.

Vaccines up 23.5% from strong Flu sales in the quarter, rebound of Travel vaccines and growth of Meningitis and PPH franchises.

Evotec SE announced the launch of “Extend”, a translational BRIDGE partnership in cooperation with CDP Venture Capital Sgr, a strategic pillar to Italy’s economic growth and innovation, and Angelini Ventures, the Corporate Venture Capital arm of the multi-business industrial group Angelini Industries.

RaySearch Laboratories AB announces that McLaren Proton Therapy Center in Flint, Michigan, has placed an order for the treatment planning system RayStation®*.

Chemomab Therapeutics Ltd . today announced that the company will participate in several scientific conferences in November.

Alterity Therapeutics Limited, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30th September 2022.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a Biologics License Application (BLA) for ONS-5010 / LYTENAVA.

AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2022.

European Medicines Agency (EMA) validates AbbVie’s Marketing Authorization Application.

ImmunoGen, Inc. today announced findings from a retrospective pooled analysis of patients who achieved extended treatment benefit (ETB) with mirvetuximab soravtansine (mirvetuximab) monotherapy across three clinical trials in folate receptor alpha (FRα)–positive recurrent ovarian cancer.